[关键词]
[摘要]
目的: 以乳腺癌细胞与成骨细胞共培养模拟乳腺癌骨转移微环境,观察在此微环境中降钙素基因相关肽( calcitonin generelated peptide,CGRP)对成骨细胞护骨素 (osteoprotegerin,OPG)及细胞核因子κB受体活化因子配体(receptor activator of nuclear factorkappa B ligand, RANKL;又称破骨细胞分化因子)表达的影响。方法:将转移性乳腺癌细胞MDAMB231或MDAMB435与成骨细胞MG63共培养,建立模拟乳腺癌骨转移微环境。行CGRP(1×108 mol/L)干预,应用RTPCR和Western Blotting技术检测干预后OPG和RANKL在mRNA和蛋白水平表达的变化。结果:MG63与MDAMB231或MDAMB435共培养环境中,RANKL mRNA及蛋白水平升高,而OPG mRNA和蛋白水平表达下降;CGRP处理后,共培养环境中RANKL mRNA及蛋白水平降低,OPG mRNA和蛋白水平升高 (均P<0.05)。结论:乳腺癌细胞能调节成骨细胞OPG/RANKL轴的表达,进而可能促进破骨细胞的活性,造成溶骨性破坏;CGRP 干预可逆转此调节作用,在乳腺癌骨转移的治疗中有潜在应用价值。
[Key word]
[Abstract]
Objective:To observe the effect of calcitonin generelated peptide (CGRP) on the expression of osteoprotegerin (OPG) and receptor activator of nuclear factorkappaB ligand (RANKL) in osteoblast cells through an in vitro breast cancer cell and osteoblast cell coculture system.Methods:The metastatic breast cancer MDAMB231 or MDAMB435 cells were cocultured with osteoblast MG63 cells to establish an in vitro microenvironment of bone metastasis of breast cancer. After treated with CGRP(1×108 mol/L), OPG and RANKL mRNA and protein expressions in osteoblast MG63 cells were examined by RTPCR and Western blotting. Results: Expression of RANKL in osteoblast MG63 cells was upregulated at both mRNA and protein levels when osteoblast MG63 cells were cocultured with breast cancer MDAMB231 or MDAMB435 cells, while those of OPG in osteoblast MG63 cells were both downregulated (P<0.05). After treatment with CGRP, expressions of RANKL in osteoblast MG63 cells were downregulated at both mRNA and protein levels, and the expressions of OPG mRNA and protein were both upregulated (P<0.05). Conclusion: Breast cancer MDAMB231 and MDAMB435 cells can promote osteolysis of osteoclast cells via regulating the expression of OPG/RANKL axis in osteoblast cells. CGRP can reverse the osteolysis of osteoblast cells induced by breast cancer cells and may serve as a potential therapeutic agent for treatment of bone metastasis of breast cancer.
[中图分类号]
[基金项目]
上海市市级医院慢性病综合防治项目(No.SHDC12007304)